Wanyu L. Lambiv

Medicine · Health Sciences

7h-index1.3kcitations32works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(23), Colorectal Cancer Treatments and Studies(20), Lung Cancer Treatments and Mutations(19), Radiomics and Machine Learning in Medical Imaging(4), MicroRNA in disease regulation(3)

Publications32 total

Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Data from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 cont. from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 cont. from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Data from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Monika E. Hegi(30), Mauro Delorenzi(26), Marie‐France Hamou(25), Annie‐Claire Diserens(24), Mathilde C.M. Kouwenhoven(23), Frank L. Heppner(22), Pierre Bady(22), Yuta Kamoshima(21), Matthias S. Matter(21), Arend Koch(21), Yasuhiro Yonekawa(21), Adrian Merlo(21), Karl Frei(21), Luigi Mariani(21), Silvia Höfer(21), Tal Shay(7), Eytan Domany(7), Roger Stupp(7), Anastasia Murat(6), Eugenia Migliavacca(4)